Although no Yap1-specific inhibitor has been approved for treating cancer patients, common Statins can target the mevalonate pathway to block Yap1 nuclear localization and Yap1 target gene expression in PDAC cells in vitro and in vivo53. Here, YAP1 is linked to cancer.